Chemours adopts new executive severance policy with 2.0x multiplier for CEO

Chemours Co

CEO severance: 2.0x sum of base salary, target annual incentive, and annualized health care subsidy; other execs 1.0x.
Payable on involuntary termination without Cause or resignation for Good Reason; requires signed release of claims.
Existing change-in-control agreements and equity award terms remain in effect; policy does not supersede them.
Policy effective October 28, 2025; administered by Board or Compensation Committee; amendment requires 12-month notice.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.